SCHEMBL5466748

SCHEMBL5466748

O=C(O)c1cc(C=C2SC(=O)N(Cc3cc(F)cc(F)c3)C2=O)ccc1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 5/20 0.58
PTPN1 P18031 7/20 0.56
ACP1 P24666 7/20 0.56
NPC1 O15118 1/20 0.53
NLRP3 Q96P20 2/20 0.50
PTPN2 P17706 1/20 0.50
MEN1 O00255 2/20 0.48
POLB P06746 2/20 0.48
KMT2A Q03164 2/20 0.48
ALDH1A1 P00352 1/20 0.48
MAPT P10636 1/20 0.48
CRHBP P24387 1/20 0.48
MAPK1 P28482 1/20 0.48
CRHR2 Q13324 1/20 0.48
NOD2 Q9HC29 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
PTPN22 Q9Y2R2 1/20 0.48
HSP90AA1 P07900 1/20 0.48
GAA P10253 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5466747 1.00 ENPP2 (0.58) ENPP2PTPN1ACP1NPC1NLRP3
SCHEMBL5461249 0.87 PTPN1 (0.59) ENPP2PTPN1ACP1NLRP3PTPN2
SCHEMBL5463880 0.87 PTPN1 (0.60) ENPP2PTPN1ACP1PTPN2MEN1
SCHEMBL5461246 0.87 PTPN1 (0.59) ENPP2PTPN1ACP1NLRP3PTPN2
SCHEMBL5463879 0.87 PTPN1 (0.60) ENPP2PTPN1ACP1PTPN2MEN1
SCHEMBL5462391 0.87 NLRP3 (0.62) ENPP2PTPN1ACP1NPC1NLRP3
SCHEMBL5462396 0.87 NLRP3 (0.62) ENPP2PTPN1ACP1NPC1NLRP3
SCHEMBL5460593 0.86 PTPN1 (0.54) ENPP2PTPN1ACP1PTPN2MEN1
SCHEMBL5460594 0.86 PTPN1 (0.54) ENPP2PTPN1ACP1PTPN2MEN1
SCHEMBL5462482 0.85 CFTR (0.62) ENPP2PTPN1ACP1NLRP3PTPN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2007-11-29 US disclosed
EP-1666469-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Institute of Medicinal Molecular Design, Inc. (JP) 2006-06-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276011-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 ENPP2 1911/4885PTPN1 3264/4885ACP1 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.